The International Gynecologic Cancer Advocacy Network is thrilled to host a virtual screening of the documentary film, Conquering Cancer on Friday March 4th at 12:30pm UTC. After the film, viewers will participate in a live Q&A panel with IGCS President, Dr. Robert Coleman and our special guest panelists championing the global push to eliminate cervical cancer.
Friday, March 4, 2022
6:30 am UTC -6 (Chicago)
12:30 pm UTC +0 (London)
8:30 pm UTC +8 (Beijing)
See more time zones.
Film Duration: 70 minutes
Live Q&A: approx. 15-20 minutes
Total duration: approx. 90 minutes
This virtual screening will be held live.
A recording will not be available after the event.
If you unable to attend our screening, visit conqueringcancercampaign.com to find another screening or host your own screening.
Tickets: $5 USD
Access Codes: We have a number of access codes to join the event at no cost reserved for cancer survivor-patients, members of the IGCS and International Gynecologic Cancer Advocacy Network and individuals residing in low- and middle-income countries.
Please enquire for access code availability by emailing firstname.lastname@example.org.
About the film, Conquering Cancer
Conquering Cancer is a feature documentary with a soaring ambition: to accelerate the elimination of cervical cancer for every woman and girl. The film brings to life stories of women who have survived cervical cancer and showcases testimonials from health care professionals who work on eliminating cervical cancer through vaccination against the human papillomavirus (HPV), screening and treatment.
Since its release, Conquering Cancer has won several awards and been shown in theatres, at professional events and to support outreach programs and has international distribution, notably on Amazon Prime, and educational distribution with Kanopy Streaming.
The burden of cervical cancer in low- and middle-income countries (LMICs)
LMICs carry a wildly disproportionate burden of cervical cancer, accounting for up to 90% of all cases and a high percentage of related deaths. This is due to lack of vaccination against HPV that causes some 70% of all cervical cancers, high-performance screening programs to detect precancerous lesions and adequate treatment. Indeed, cervical cancer posts an average five-year survival rate of 90% when detected and treated early as is generally the case in high-income regions.
According to the World Health Organization’s Global Strategy, financing elimination is affordable, at an average cost of USD 0.40 per person per year in low-income settings and USD 0.20 in lower-middle-income countries.
Dr. Daniela Luvero
Dr. Luvero is a gynecologist at University Hospital Campus Bio Medico of Rome, in Italy. She received a PhD in oncology at the same University in 2021. She worked as Clinical fellow at UCLH in London in the Department of Oncology for 1 year and she has a strong interest in research and has been involved in several international trials as coinvestigator, authored/co-authored many peer reviewed publications.
Dr. Luvero is active in the global gynecological oncology community, and she is currently the European Representative for the IGCS Council and in 2022 she became the Chief of the Advocacy Committee for the International Gynecologic Cancer Advocacy Network.
Dr. René Pareja
Dr. Pareja is a Gynecologist Oncologist at Astorga Oncology Clinic in Medellín and the National Cancer Institute in Bogotá, Colombia
He is an Associate Editor of the International Journal Gynecological Cancer and a reviewer for more than 20 specialty journals, authoring 9 book chapters and more than 70 publications in peer-reviewed journals.
He is currently a member of the board of directors of the International Gynecological Cancer Society and FIGO Gynaecological Cancer Committee
In 2021, he was honored with the IGCS Award for Community Advancement in Resource-Limited Settings in recognition for his outreach throughout Latin America and beyond. René has been an amazing teacher for fellows in Colombia and served as an International Mentor for the IGCS Global Curriculum and Mentorship Program in Guatemala. He also helps established doctors and trainees throughout Latin America often serving as a catalyst for collaborative efforts to increase access to education and training in the region.
Dr. Ida Ismail-Pratt
Special interest: Education and training, screening and prevention of HPV related diseases and colposcopy. She is currently an OBGYN specialist and medical director for The Obstetrics & Gynaecology Centre in Singapore.
Dr. Ida championed the introduction of HPV DNA test in Singapore and co-chair the Singapore national cervical screening program implementation committee introducing HPV primary screening into Singapore in May 2019.
She is the Vice President of the Society of Colposcopy & Cervical Pathology Singapore (SCCPS). She has been actively promoting public education and awareness in Singapore through various societies in Singapore such as Singapore Cancer Society and Alliance Against HPV (A4HPV) particular for the young generations.
Internationally, she co-led the development of the IGCS Global cervical preinvasive disease training program. She is also is part of the education committee for the International Papillomavirus Society (IPVS) and led the IPVS ECHO committee program. She is also the secretary and founding member of the Asia Pacific HPV Coalition, a selected group of experts in the APAC region working together focusing on cervical cancer elimination in the Asia Pacific through research, education and awareness.
Dr. Kathleen Schmeler
Dr. Kathleen Schmeler is a Professor of Gynecologic Oncology at The University of Texas MD Anderson Cancer Center. She is also the Executive Director of Global Oncology for the MD Anderson Cancer Network. Her research interest is in cervical cancer prevention and treatment, particularly for resource-constrained countries and medically underserved communities in the US. She is the Past-Chair of the IGCS Training & Mentoring Committee.
Prof. Dr. Woo Yin Ling
Professor Dr. Woo Yin Ling is a Consultant Gynaecological Oncologist at University Malaya Medical Centre, and a professor at the Department of Obstetrics and Gynaecology, Faculty of Medicine at the University of Malaya.
She received her medical degree from Trinity College, Dublin, and her PhD from the University of Cambridge, England. She is also the recipient of multiple international awards in recognition for her professional achievements. In 2021, she received the FIGO award in recognition her contribution to women’s health.
Dr. Woo’s areas of is in the management of gynaecological malignancies, particularly cervical cancer. Dr. Woo is currently the country representative (Malaysia) for the Asia-Oceania Research Organisation in Genital Infection and Neoplasia (AOGIN), taskforce member for the Malaysian policy change to Primary HPV screening for cervical cancer, member of the Asia Pacific Economic Consortium (APEC) Cervical Cancer working group and is the founding trustee for ROSE Foundation.
Moderated by IGCS President, Dr. Robert L. Coleman (USA)
Dr. Coleman completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois, and completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. Prior to joining the M.D. Anderson faculty in 2004, he served as Vice-Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center in Dallas. At M.D. Anderson, Dr. Coleman was a Professor and served as the Executive Director for Cancer Network Research, holding the Ann Rife Cox Chair in Gynecology. In March 2020, he joined US Oncology Research as their Chief Scientific Officer.
Dr. Coleman has authored or coauthored over 700 scientific publications, including over 400 peer-reviewed articles, along with numerous book chapters, monographs, invited articles, and textbooks. In 2019, he received the 2019 APGO-CREOG award for Excellence in Teaching. He is a co-Director for GOG-Partners and serves on the Board of Directors for GOG-Foundation, Inc. He currently serves as President of the International Gynecologic Cancer Society (IGCS) and was recently inducted into MJH Life Sciences™ 2020 class of “Giants in Cancer Care®.”